BACKGROUND: Improved understanding of disease biology of head and neck squamous cell carcinoma (HNSCC) with nearly universal expression of EGFR has led to the introduction of targeted therapies to interrupt signalling of this negative prognostic marker. OBJECTIVE: We performed a literature review on the mechanisms and efficacy of anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in patients with locally advanced or recurrent/metastatic HNSCC. RESULTS/ CONCLUSION: Clinical trials in HNSCC have administered EGFR directed drugs as single agents, in combination with chemotherapy or radiotherapy and demonstrated a good safety profile with antitumour activity in a subgroup of patients. The biology of responsiveness is still unclear, although there is growing evidence of an association of skin toxicity or presence of shorter EGFR intron 1 cytosine-adenine repeats with positive outcome.
BACKGROUND: Improved understanding of disease biology of head and neck squamous cell carcinoma (HNSCC) with nearly universal expression of EGFR has led to the introduction of targeted therapies to interrupt signalling of this negative prognostic marker. OBJECTIVE: We performed a literature review on the mechanisms and efficacy of anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in patients with locally advanced or recurrent/metastatic HNSCC. RESULTS/ CONCLUSION: Clinical trials in HNSCC have administered EGFR directed drugs as single agents, in combination with chemotherapy or radiotherapy and demonstrated a good safety profile with antitumour activity in a subgroup of patients. The biology of responsiveness is still unclear, although there is growing evidence of an association of skin toxicity or presence of shorter EGFR intron 1 cytosine-adenine repeats with positive outcome.
Authors: Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber Journal: Am J Pathol Date: 2011-02 Impact factor: 4.307
Authors: Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis Journal: Clin Cancer Res Date: 2010-04-13 Impact factor: 12.531
Authors: Dirk Strumberg; Beate Schultheis; M E Scheulen; R A Hilger; J Krauss; N Marschner; F Lordick; F Bach; D Reuter; L Edler; K Mross Journal: Invest New Drugs Date: 2010-12-21 Impact factor: 3.850
Authors: Christian Freudlsperger; Jeffrey R Burnett; Jay A Friedman; Vishnu R Kannabiran; Zhong Chen; Carter Van Waes Journal: Expert Opin Ther Targets Date: 2010-11-26 Impact factor: 6.902
Authors: Benson G Ongarora; Krystal R Fontenot; Xiaoke Hu; Inder Sehgal; Seetharama D Satyanarayana-Jois; M Graça H Vicente Journal: J Med Chem Date: 2012-04-18 Impact factor: 7.446
Authors: Adam T Koch; Laurie Love-Homan; Madelyn Espinosa-Cotton; Aditya Stanam; Andrean L Simons Journal: Cancer Res Date: 2015-02-20 Impact factor: 12.701
Authors: Sufi M Thomas; Bichismita Sahu; Srinivas Rapireddy; Raman Bahal; Sarah E Wheeler; Eva M Procopio; Joseph Kim; Sonali C Joyce; Sarah Contrucci; Yun Wang; Simion I Chiosea; Kira L Lathrop; Simon Watkins; Jennifer R Grandis; Bruce A Armitage; Danith H Ly Journal: ACS Chem Biol Date: 2012-11-09 Impact factor: 5.100